Grey matter volumes may predict the clinical response to paliperidone palmitate long-acting in acute psychosis: a pilot longitudinal neuroimaging study

In schizophrenia, paliperidone palmitate (PP) long acting injectable (LAI) has been reported to sustain plasma concentrations and improve clinical symptoms. Moreover, it has also been demonstrated the important role of total gray matter (GM) volumes in predicting the clinical outcome. However, no studies investigating the association between PP-LAI treatment and brain morphometry has been published so far. Therefore, the main aim of our 24 weeks prospective observational exploratory study was to investigate the relation between brain anatomy and clinical outcome in seven patients with acute psychosis treated with PP-LAI.

Source: Psychiatry Research: Neuroimaging - January 24, 2017 Category: Psychiatry Authors: Carlo Altamura, Giuseppe Delvecchio, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Alessio Fiorentini, M. Donatella Mirabile, Riccardo A. Paoli, Claudia Cinnante, Fabio Triulzi, Massimo C. Mauri, Paolo Brambilla Source Type: research